Trials / Completed
CompletedNCT00338312
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 52 Weeks and Safety for 52 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 610 (actual)
- Sponsor
- Warner Chilcott · Industry
- Sex
- Female
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
Detailed description
Naturally menopausal women with hypoactive sexual desire disorder (HSDD) were randomized into a 52-week, multicenter, double-blind (DB), parallel-group, placebo-controlled study. Patients were stratified based on presence/absence of uterus and randomized to receive placebo or testosterone transdermal system. Patients had to maintain a stable dose of estrogen/progestin throughout the study. Patients who completed the first 52 weeks of the study were given the opportunity to participate in year 2-4 open-label (active treatment) study extension which was added to the protocol by amendment. Safety was assessed by adverse events, lipids, serum chemistry with hepatic, renal and carbohydrate metabois in evaluation, coagulation testing, and hermatology. Physical exam including clinical assessments of facial hair and acne were monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone Transdermal System | testosterone patch (300 mcg/day) patch changed 2 times/week, for one year |
| DRUG | Placebo patch | placebo patch changed twice a week for one year |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2004-12-01
- Completion
- 2006-07-01
- First posted
- 2006-06-20
- Last updated
- 2013-04-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00338312. Inclusion in this directory is not an endorsement.